{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.61","value":"26.9"},{"groupId":"OG001","spread":"28.49","value":"28.2"},{"groupId":"OG002","spread":"29.02","value":"35.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning. The total OSDI score was calculated as (sum of scores for all questions answered\\*100) divided by (total number of questions answered\\*4). Domain scores ranged from 0 to 100; lower scores are better. Therefore, decrease in score from Baseline means improvement. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for worst-case post Baseline is presented.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 2.5 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 39 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG000","title":"Main Study: GSK2857916 2.5 mg/kg (Frozen Liquid)"},{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 3.4 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 32 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG001","title":"Main Study: GSK2857916 3.4 mg/kg (Frozen Liquid)"},{"description":"Participants were administered lyophilized powder (100 mg/vial in a single use vial) at a dose of 3.4 mg/kg GSK2857916 given IV for a maximum of 35 cycles (1 cycle= 21 days). Lyophilized powder was reconstituted using water for injection.","id":"OG002","title":"Main Study: GSK2857916 3.4 mg/kg (Lyophilized)"}],"paramType":"MEAN","populationDescription":"Full Safety Population. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to Week 186","title":"Worst Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}